NCT00273910View on ClinicalTrials.gov

Evaluation of the Impact of Adjuvants Accompanying Peptide Immunization in High-Risk Melanoma

PHASE2CompletedINTERVENTIONAL
Enrollment

104

Participants

Timeline

Start Date

January 31, 2006

Primary Completion Date

May 31, 2010

Study Completion Date

May 31, 2010

Conditions
High-Risk Melanoma
Interventions
DRUG

gp100:209-217 (210M)

DRUG

Montanide ISA-51

DRUG

Imiquimod

Apply imiquimod 5% cream to the skin at the site of injection daily for 5 days

Trial Locations (1)

20892

National Cancer Institute (NCI), Bethesda

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00273910 - Evaluation of the Impact of Adjuvants Accompanying Peptide Immunization in High-Risk Melanoma | Biotech Hunter | Biotech Hunter